Evolent Health (NYSE:EVH) Price Target Cut to $15.00 by Analysts at JPMorgan Chase & Co.

Evolent Health (NYSE:EVH) had its price objective lowered by JPMorgan Chase & Co. from $45.00 to $15.00 in a research note issued to investors on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the technology company’s stock.

EVH has been the topic of a number of other research reports. Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $38.00 to $16.00 in a research note on Friday, November 8th. Barclays cut their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Royal Bank of Canada restated an “outperform” rating and issued a $20.00 target price on shares of Evolent Health in a report on Tuesday, November 12th. KeyCorp started coverage on Evolent Health in a report on Friday, October 11th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Truist Financial restated a “buy” rating and set a $33.00 price objective on shares of Evolent Health in a research report on Tuesday, August 27th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.90.

Evolent Health Price Performance

EVH opened at $11.25 on Friday. The business has a fifty day simple moving average of $23.63 and a 200-day simple moving average of $23.91. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. Evolent Health has a fifty-two week low of $11.17 and a fifty-two week high of $35.00.

Institutional Investors Weigh In On Evolent Health

Large investors have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its stake in shares of Evolent Health by 3.2% during the 2nd quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company’s stock worth $298,000 after acquiring an additional 480 shares in the last quarter. Ascent Group LLC boosted its position in Evolent Health by 2.8% during the first quarter. Ascent Group LLC now owns 20,330 shares of the technology company’s stock worth $667,000 after purchasing an additional 550 shares during the period. SeaCrest Wealth Management LLC grew its holdings in Evolent Health by 6.3% during the second quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company’s stock valued at $195,000 after purchasing an additional 600 shares during the last quarter. American International Group Inc. raised its position in shares of Evolent Health by 1.2% in the first quarter. American International Group Inc. now owns 55,402 shares of the technology company’s stock valued at $1,817,000 after purchasing an additional 640 shares during the period. Finally, Arizona State Retirement System lifted its stake in shares of Evolent Health by 2.3% in the second quarter. Arizona State Retirement System now owns 29,083 shares of the technology company’s stock worth $556,000 after buying an additional 649 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.